Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Shares Issued (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Shares Issued data on record, last reported at -$21.4 million in Q3 2025.

  • For Q3 2025, Shares Issued rose 1.69% year-over-year to -$21.4 million; the TTM value through Sep 2025 reached $7.2 million, up 1350.61%, while the annual FY2024 figure was $7.1 million, N/A changed from the prior year.
  • Shares Issued reached -$21.4 million in Q3 2025 per SGMO's latest filing, down from $11.2 million in the prior quarter.
  • Across five years, Shares Issued topped out at $22.5 million in Q1 2024 and bottomed at -$21.8 million in Q3 2024.
  • Average Shares Issued over 5 years is $769647.1, with a median of $880000.0 recorded in 2021.
  • The widest YoY moves for Shares Issued: up 94306.25% in 2023, down 42411.76% in 2023.
  • A 5-year view of Shares Issued shows it stood at $1.1 million in 2021, then tumbled by 96.81% to $34000.0 in 2022, then plummeted by 2214.71% to -$719000.0 in 2023, then skyrocketed by 1071.63% to $7.0 million in 2024, then tumbled by 406.46% to -$21.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were -$21.4 million in Q3 2025, $11.2 million in Q2 2025, and $10.4 million in Q1 2025.